Smartest Doc
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis
Inflammatory Bowel Disease, 06/01/2012
Clinical Article
Feagan BG et al. – The failure to demonstrate a superior rate of adherence to OD dosing may be due to the high rate of adherence observed in the clinical trials environment.
Methods- Eleven studies that evaluated 4070 patients were identified.
- The risk of bias was low for most factors, although five studies were single–blind and one was open–label.
- No difference was observed between the dosing strategies in the proportion of patients with clinical remission (relative risk [RR] 0.95; 95% confidence interval [CI] 0.82–1.10), clinical improvement (RR 0.87 95% CI 0.68–1.10), or relapse at 6 (RR 1.10; 95% CI 0.83–1.46) or 12 months (RR 0.92; 95% CI 0.83–1.03).
- Subgroup analyses showed no important differences in efficacy.
- No significant difference was demonstrated in rates of medication adherence or adverse events between OD and conventional dosing.
- OD mesalamine appears to be as effective and safe as conventional dosing for both the treatment of mild to moderately active UC and for maintenance of remission in quiescent UC.
